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Abstract
Background: The inhibitory CTLA-4 molecule is a crucial regulator of immune responses and a target for therapeutic
intervention in both autoimmunity and cancer. In particular, CTLA-4 is important in controlling antigen-specific immunity,
including responses to autoantigens associated with autoimmune disease. Here, we investigate cytokine responses to a
range of lupus-associated autoantigens and assess whether the alternatively spliced isoform of CTLA-4, soluble CTLA-4
(sCTLA-4), contributes to immune regulation of autoantigen-specific immunity in systemic lupus erythematosus (SLE).
Methods: The cell culture supernatant production of sCTLA-4 as well as the cytokines IL-10, IFN-γ, and IL-17 from
peripheral blood mononuclear cells (PBMC) from lupus patients and age- and sex-matched healthy volunteer
donors were measured in response to previously identified histone and small nuclear ribonucleoprotein (snRNP)
autoantigen-derived peptides (H391-105, H471-93, and U170K131-151) by ELISA. We also examined the functional
contribution of sCTLA-4 to immune regulation in the context of these autoantigenic peptides following blockade
of sCTLA-4 with a selective anti-sCTLA-4 monoclonal antibody, JMW-3B3.
Results: We identified responses to autoantigenic peptides, which revealed qualitative differences in cytokine
(IL-10, IL-17, and IFN-γ) profiles between SLE patients and healthy donors. PBMC from healthy donors responded
to each of the lupus peptides by secreting IFN-γ and IL-17, but PBMC from SLE patients produced IL-10. Although we
did not observe differences in the levels of serum or PBMC culture supernatant sCTLA-4 in either cohort, blockade of
sCTLA-4 in PBMC cultures responding to antigen enhanced the cytokine profiles associated with each group.
Conclusion: The results show that lupus autoantigen-derived peptides display varied immunogenicity in lupus versus
healthy volunteer donors, while sCTLA-4 acts to regulate the T-cell activity independently of response profile.
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Background
Systemic lupus erythematosus (SLE) is a multisystem
autoimmune disorder characterised by a range of clin-
ical manifestations including arthritis, nephritis, central
nervous system disease, alopecia, and photosensitivity.
The disease is most prominent among women in their
child-bearing years and, despite recent improvements
in therapeutic options, many patients experience poor
treatment outcomes [1]. At a molecular level, dysregu-
lated apoptosis, inefficient clearance of cellular debris,
and enhanced cytokine activity, notably interleukin
(IL)-10 and interferon (IFN)-α, all appear to be import-
ant factors contributing to the inflammatory disease
process [2].
Chronically activated autoantigen-specific T cells that
promote production of high-affinity autoantibodies spe-
cific for nucleic acids/nucleic acid binding proteins are
also factors in SLE [3–6]. These autoreactive T cells are
driven primarily by recognition of self-peptides derived
primarily from the same nucleic acid binding proteins
that represent the main targets of the autoimmune
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response in lupus, e.g. histones [7]. Although these pep-
tide autoantigens can drive pathological processes in
lupus, interestingly they can also induce tolerance by in-
fluencing increased regulatory T-cell (Treg) activity, or
by stimulating production of anti-inflammatory cyto-
kines such as IL-10. The administration of self-peptides
to promote tolerogenic responses in lupus has already
been successful in murine models of lupus with one
such peptide, Lupozor™, progressing through to clinical
trials as a specific immunotherapy for the treatment of
lupus [8, 9]. Peptides as therapeutics are thus very inte-
resting because they are relatively cheap to produce and
purify compared with biologics and can be more easily
administered [10].
Analysis of cytokine responses in lupus patients driven
by autoantigenic peptides has demonstrated a certain
amount of heterogeneity in terms of the cytokine pro-
files stimulated by particular peptides, suggesting that
some peptides may preferentially drive regulatory im-
mune responses, e.g. by producing IL-10, and others a
more typical effector T-cell cytokine response, e.g. IFN-γ
[3], but while these response differences were identified
in individual lupus patients it is unclear as to whether
any particular profile is solely typical of lupus disease or
if healthy donors also raise similar response patterns or
any response at all to these lupus-associated peptides. Fi-
nally, the recent emergence of T helper (Th)17 T cells
and their relevance to SLE raises the question of whether
these peptides might drive IL-17 production [11].
Cytotoxic T lymphocyte antigen 4 (CTLA-4) is an
inhibitory cell-surface receptor central to immune regu-
lation and is predominantly expressed by Treg and
activated CD4+ T-effector cells [12, 13]. CTLA-4 has
become one of the most clinically exploited immune
molecules of the last decade. Notably, augmenting
CTLA-4 function by infusing the recombinant soluble
form of CTLA-4 called CTLA4-Ig (or abatacept) select-
ively inhibits T-cell co-stimulation and is beneficial for
treating some autoimmune diseases, notably rheumatoid
arthritis [14]. CTLA4-Ig is currently approved for the
treatment of rheumatoid arthritis, but in SLE its benefits
have been more difficult to establish, even though its
immunosuppressive effects were first clearly established
in lupus mouse models [15]. A recent phase II clinical
trial showed no overall patient benefit for this therapy,
despite anecdotal reports that it benefited individual
patients [16].
While natural CTLA-4 is generally considered as a
cell-surface receptor, it can also be produced as a natur-
ally secreted soluble molecule [17–19]. This natural sol-
uble CTLA-4 (sCTLA-4) lacks the transmembrane
domain of the full-length CTLA-4 receptor and carries a
different C-terminal amino acid sequence, but crucially re-
tains the capacity to engage with B7 ligands [18]. Thus, this
secretable isoform has the potential to influence immune
responses including those associated with autoimmune dis-
ease. Little is known of any regulatory role for natural
sCTLA-4 in this respect although serum levels of sCTLA-
4 are higher in SLE patient cohorts and other autoimmune
diseases compared with healthy individuals [20, 21]. Fur-
thermore, it is not known if sCTLA-4 might regulate auto-
antigenic T cells stimulated by self-peptides in lupus.
Here, we investigated the role of previously identified
peptide autoantigens (H2B10-33, H391-105, H471-93, SmB136-
153, and U170K131-151) [3, 22, 23] by comparing peripheral
blood mononuclear cell (PBMC) responses derived from
lupus patients or healthy volunteer study participants to
determine whether particular effector or regulatory pep-
tide driven responses are distinctive to lupus disease and,
further, whether natural sCTLA-4 has a regulatory influ-
ence over those responses.
Methods
Donors and sample preparation
Blood samples were collected by venepuncture into hepa-
ran sulphate-containing vacutainers from lupus patients
attending either the Rheumatology or Vasculitis depart-
ment at Aberdeen Royal Infirmary (see Table 1 for demo-
graphic summary), and age- and sex-matched healthy
volunteer donors with informed consent. Only patients
Table 1 Demographic and clinical characteristics of the lupus
patient study group
Demographic and clinical characteristics Number of SLE patients
Age, years 48.1 ± 14.7
Sex, female/male 113/14
Renal disease 37 (29)
Arthritis 54 (43)
Serositis 38 (30)
Haematological disorder 82 (65)
Neurological disorder 24 (19)
Immunological disorder 119 (94)
Anti-dsDNA 40 (38)
ANA 104 (82)
Anti-phospholipid syndrome 18 (14)
Low C3 27 (22)
Low C4 44 (36)
Prednisolone <7.5 mg daily 39 (31)
Prednisolone >7.5 mg daily 17 (13)
Anti-malarials 82 (65)
Azathioprine, MTX, or mycophenolate mofetil 46 (36)
SLICC/ACR Damage Index, mean ± SD (range) 0.85 ± 1.2 (0–8)
Except where indicated otherwise, values are number (%) of patients
Anti-dsDNA anti-double-stranded DNA, ANA anti-nuclear antigen, MTX methotrexate,
SLE systemic lupus erythematosus, SLICC/ACR Systemic Lupus International
Collaborating Clinics/American College of Rheumatology
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with an existing diagnosis of SLE were recruited into the
study. In addition, disease duration, evidence of existing
disorders, serological analysis, and current medication
were recorded. Age groups were clustered into four age
ranges: 18–25, 26–35, 36–50, and 51+. Patients under the
age of 18 or with pre-determined HIV status were
excluded from the study. Ethical approval was obtained
from the East of Scotland Research Ethics Committee (ref:
REC 10/S1401/20). PBMC were prepared by Lymphoprep
1.077 (Axis Shield, Dundee, UK) density gradient centrifu-
gation and cultured essentially as previously described
[24] in RPMI 1640 medium (Invitrogen, Paisley, UK)
supplemented with 5 % autologous human serum in an
atmosphere of 37 °C, 5 % CO2; 1 × 10
6 PBMC were
cultured for 5 days in 1-ml wells unless otherwise stated.
T-cell stimuli and autoantigens
Histone peptides H2B (10PKKGSKKAVTKAQKKDGKK
RKRSR33), H3 (91QSSAVMALQEASEAY105), and H4
(71TYTEHAKRKTVTAMDVVYALKRQ93), Spliceoso-
mal peptide (SmB 136GPSQQVMTPQGRGTVAAA153),
and U1 small nuclear ribonucleoprotein of 70kDa (U1
70K 131RIHMVYSKRSGKPRGYAFIEY151) were used in
the non-phosphorylated form (GL Biochem, Shanghai,
China). Peptides were at least 90 % pure as determined
by reverse phase HPLC and Maldi-T of mass spectroscopy
and dissolved in 5 % DMSO/endotoxin-free Hank’s bal-
anced saline solution with phenol red (HBSS). Each
peptide was each added to cell cultures at 5, 10, and 20
μg/ml, unless stated otherwise. Additionally, cells were
stimulated with anti-CD3 mAb (OKT-3, 2 μg/ml),
tuberculin purified protein derivative (PPD; Statens
Serum Institut, Copenhagen, Denmark; 5 μg/ml), and
Staphylococcal enterotoxin B (SEB; Sigma-Aldrich, Poole,
Dorset, UK; 0.5 μg/ml).
T-cell proliferative responses and antibody blockade
Cell proliferation was measured by 3H thymidine incorp-
oration in duplicate samples using a 1450 Microbeta li-
quid scintillation counter (LKB Wallac, Turku, Finland).
Results are presented as mean counts per minute (CPM).
Anti-sCTLA-4 blockade responses were performed with
the JMW-3B3 anti-sCTLA-4 mAb, developed in-house
at the University of Aberdeen. JMW-3B3 is an IgG1λ
antibody that selectively binds sCTLA-4 and has pre-
viously been demonstrated to enhance antigen-specific
immune responses compared with an IgG1 isotype
control [25]. Enhanced responses were similar to ini-
tial adsorption experiments with AS-33P anti-CTLA-4
mAb (Antibody Solutions, Sunnyvale, CA, USA). Fresh
antibody preparations were tested for the presence of
endotoxin and stored without preservative at –20 °C prior
to use.
Cytokine ELISA
ELISA for cytokines in cell cultures was based on previ-
ously published methods [26]. Antibody pairs were: anti-
IFN-γ (clones NIB42 and 4S.B3; BD Biosciences, Oxford,
UK), anti-IL-17A (clones eBio64CAP17 and eBio64DEC17;
eBiosciences, Hatfield, UK), anti-IL-10 (clones JES3-19 F1
and JES3-12G8; BD Biosciences, Oxford, UK), and IFN-α
(clones MT1/3/5 and MT2/4/6; Mabtech, Sweden). Cyto-
kine standards (IL-10, IL-17, IFN-γ) were from Peprotech
EC Ltd. (London, UK), and IFN-α was from Mabtech.
Bound antibody was detected using streptavidin-labelled al-
kaline phosphatase with a phosphate substrate (both Sigma
Aldrich), and absorbance measured at 450 nm (corrected
with a reference reading at 492 nm) with a Multiskan MS
microplate photometer (Life and Laboratory Sciences,
Basingstoke, UK). Cell culture supernatant levels of cyto-
kine were measured following 5 days culture of PBMC at
37 °C, 5 % CO2.
Soluble CTLA-4 ELISA
The selective ELISA for human sCTLA-4 used the anti-
CTLA-4 murine mAb clone BNI3 (2 μg/ml) as a capture
reagent, and biotinylated JMW-3B3 [25] as the sCTLA-
4-specific detection reagent according to the protocol
described for the cytokine ELISA above. Affinity-purified
sCTLA-4 was used to construct standard curves.
Data analysis
For greater clarity in the main figures, and for comparison
of peptide- or control antigen-induced responses, all data
are presented as Stimulation Indices (SI), i.e. the rates of
stimulated versus resting cell responses. The full datasets
are also presented in Additional file 1 together with a
comprehensive statistical analysis (Prism GraphPad). SI
values above 2 (i.e. double resting cell levels) were consi-
dered positive.
Results
Soluble CTLA-4 levels in serum and PBMC cell culture
supernatants of lupus patients
Previous reports identified relatively high serum levels of
sCTLA-4 in SLE patients [20, 21], but that work used
antibodies capable of binding either native sCTLA-4,
exocytosed full-length CTLA-4, or fragments of the
extracellular domain of CTLA-4 cleaved from the cell
surface. To ensure only sCTLA-4 and not cleaved prod-
ucts were detected, we used an antibody selective for a
unique sequence of sCTLA-4 to analyse cell culture
supernatant and serum levels of sCTLA-4 [25].
First, we measured levels of T helper-associated effector
cytokines and sCTLA-4 in cell culture supernatants from
resting PBMC, as well as sera from SLE patients and
healthy donors and age- and sex-matched healthy volun-
teer donors (Fig. 1). As expected, median supernatant
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levels of IFN-γ and IFN-α in patient PBMC resting cell
cultures were significantly higher than those of healthy
volunteer donors (IFN-γ: 173.8 pg/ml versus 77.0 pg/ml,
p < 0.05; IFN-α: 988.5 pg/ml versus 94.8 pg/ml, p < 0.0001;
Mann-Whitney U test) but no significant difference in cel-
lular proliferation (180 versus 158 CPM) or the cytokines
IL-10 (668.9 pg/ml versus 702.3 pg/ml), IL-17 (87.7 versus
44.4 pg/ml), or sCTLA-4 (292.1 versus 552.5 pg/ml) was
observed (Fig. 1). Levels of sCTLA-4 in supernatants from
lupus patient PBMC varied widely between individuals
(range 0–4288 pg/ml; Fig. 1). However, cell culture
sCTLA-4 levels from the healthy donor cohort also varied
widely (range 0–4027 pg/ml; Fig. 1). A similar pattern was
observed in serum sCTLA-4 levels from SLE patients
(range 0–6326 pg/ml, median 1044.0 pg/ml; Fig. 2) com-
pared with sera from healthy donors (range 0–4421 pg/
ml, median 792.4 pg/ml). In this analysis, in contrast to
previous studies [20], despite an overall increase in serum
levels of sCTLA-4, there was no significant difference
between the healthy and patient donor cohort.
Effect of sCTLA-4 on responses to peptide autoantigens
in PBMC from lupus patients or healthy volunteer donors
Previously, sCTLA-4 was demonstrated to regulate cyto-
kine responses in PBMC and T cells, but its regulatory
effects in autoimmune disease have not been examined.
Fig. 1 Resting levels of cellular proliferation and cell culture supernatant
cytokines IFN-γ, IL-17, IL-10, IFN-α, and sCTLA-4 isolated from PBMC of
SLE patients or age- and sex-matched healthy donors following
incubation for 5 days (n = 45 per group; *p < 0.05, **p < 0.01,
***p < 0.001, non-parametric Mann-Whitney U test). CPM counts
per minute, IFN interferon, IL interluekin, ns not significant,
sCTLA-4 soluble cytotoxic T lymphocyte antigen 4, SLE systemic
lupus erythematosus
Fig. 2 Serum levels of sCTLA-4 in SLE patients compared with age- and
sex-matched healthy donors measured by ELISA (n= 45 per group; non-
parametric Mann-Whitney U test). ns not significant, sCTLA-4 soluble
cytotoxic T lymphocyte antigen 4, SLE systemic lupus erythematosus
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Strong stimuli (e.g. anti-CD3 mAb) can temporarily
suppress sCTLA-4 expression and production but, in
healthy PBMC, more physiological stimuli (e.g. recall
antigens) actually maintain sCTLA-4 levels and may
even increase production [25]. To examine sCTLA-4
production in lupus, we investigated five peptide auto-
antigens identified in previous studies for their capacity
to influence sCTLA-4 production.
Three of the five peptides examined (H391-105, H471-
93, and U170K131-151; see Methods and materials for
sequences) stimulated PBMC responses in the majority
of both SLE patients and, unexpectedly, healthy do-
nors, confirming their immunogenicity as determined
by previous studies (summary of stimulation indices
for H391-105, H471-93, and U170K131-151 are shown in
Fig. 3a, and full individual datasets and statistical ana-
lysis are shown in Additional file 1, n = 45 per group).
Two further peptides, H2B10-33 and SmB136-153, did
not stimulate significant responses in either cohort.
Healthy donor PBMC proliferated vigorously and
produced significantly higher amounts of the effector
cytokines IFN-γ and IL-17 in response to peptides
U170K131-151, H391-105, and H471-93 (n = 43; Fig. 3a and
Additional file 1). Each of these peptides also induced
lower but significant increases in IL-10 production
compared with resting cells with a mean SI of 5 or less
depending on the peptide and peptide dose. These
healthy donors were, in effect, mounting a response
characteristic of a mixed Th1/Th17 T-cell response to
these lupus peptide autoantigens.
In contrast to healthy donors, SLE patient responses
were characterised by increased production of IL-10 to
the peptides rather than increased IFN-γ and IL-17. Des-
pite production of immunosuppressive IL-10, PBMC
from the SLE patient cohort significantly increased levels
of cell proliferation to the peptides compared with
resting cells, although levels were significantly lower
than those observed in healthy donors (p < 0.01, Mann
Whitney). Thus, this initial assessment of anti-peptide
cytokine responses revealed a clear differentiation in
cytokine profile between healthy and SLE patient
donors.
We concurrently examined sCTLA-4 supernatant
levels and, despite individual donors mounting large
sCTLA-4 increases to the peptides, as a population both
patient and healthy donor levels of sCTLA-4 were not
significantly increased or decreased (Additional file 1).
To determine whether lupus patients would respond
in the same way as healthy donors regarding sCTLA-4
production by PBMC stimulated by antigens rather
than autoantigens, we examined a panel of stimulants,
including PPD recall antigen, SEB superantigen, and
agonist anti-CD3 mAb (Fig. 3b). Mean SI levels of
sCTLA-4 were generally higher upon stimulation with
PPD recall antigen in both patient and healthy donor
cohorts and SEB in the lupus patient cohort, although
levels were not statistically significant compared with
resting PBMC (Wilcoxon). Further analysis revealed
that the mean increase in SI primarily came from just a
few individual donors that responded to PPD by secreting
increased amounts of sCTLA-4 in an antigen-dependent
manner. Reduction of sCTLA-4 by stimulation of PBMC
with high doses of anti-CD3 mAb has been observed
[17, 19] (Fig. 3b and Additional file 1) and was similar
here [25].
Effect of anti-sCTLA-4 antibody blockade on autoantigen-
specific immune responses in lupus patients
Previously, we demonstrated in healthy donors that nat-
urally secreted sCTLA-4 contributes to the regulation of
antigen-specific effector T-cell responses by regulatory T
cells, and that blocking its activity with a soluble CTLA-
4 selective antibody can enhance T-effector response
intensity compared with an IgG1 isotype control [25].
Little is known, however, whether amplification of such
responses is intact in the context of autoimmunity. We
therefore investigated the effects of sCTLA-4 blockade
in lupus patients or healthy volunteer donors. Blockade
of sCTLA-4 with the anti-sCTLA-4 mAb JMW-3B3
reduced supernatant levels of detectable sCTLA-4 by
more than 92 % (n = 24 donors; p < 0.0001, Wilcoxon).
We first assessed whether sCTLA-4 inhibition in cell
cultures stimulated with lupus peptide autoantigens
would affect any aspect of effector T-cell activity. Inhib-
ition of sCTLA-4 in healthy donor cell cultures stimu-
lated with U170K131-151, H391-105, and H471-93 had
mixed effects on effector cytokine production and cell
proliferation specific to each peptide, and were generally
also individual to particular donors (summarised in
Table 2 for both healthy and lupus donors). Blockade of
sCTLA-4 in the healthy donor cohort generally sup-
pressed or did not alter cell proliferation and cytokine
production (Fig. 4 and summarised in Table 2; p < 0.05,
Wilcoxon), while the SLE cohort following sCTLA-4
inhibition significantly enhanced the prevailing IL-10
cytokine phenotype stimulated by the peptides. Over-
all, our assessment of the effects of sCTLA-4 blockade
on anti-peptide PBMC responses from healthy and
lupus donors indicates that PBMC from the lupus co-
hort were more sensitive to changes in IL-10 levels fol-
lowing removal of the suppressive effects of sCTLA-4
suggesting that, nevertheless, sCTLA-4 suppresses ef-
fector T-cell responses independent of the profile of
cytokine(s) it is producing.
An interesting corollary to the investigation of sCTLA-4
blockade on peptides was the same assessment of the
effects on recall responses in lupus patients compared
with healthy donors, where healthy donor PBMC were
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Fig. 3 Analysis and summary of PBMC responses from healthy donors or SLE patients to peptide autoantigens H391-105, H471-93, and U170K131-151
at concentrations of 10 and 20 μg/ml (a) and PPD (5 μg/ml), SEB (0.5 μg/ml), and anti-CD3 mAb (2 μg/ml) control stimulants (b), before analysis
of cellular proliferation, and levels of cell culture supernatant cytokine (IFN-γ, IL-17, IL-10, and sCTLA-4; n = 45; *p < 0.05 **p < 0.01, ***p < 0.001,
non-parametric Mann-Whitney U test). Stimulation indices (SI), defined as fold-increase in response compared with resting cell controls, are shown
for clarity with full data sets and statistical analysis shown in Additional file 1. IL interleukin, ns not significant, PPD purified protein derivative,
sCTLA-4 soluble cytotoxic T lymphocyte antigen 4, SEB Staphylococcal enterotoxin B, CD cluster of differentiation
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enhanced to PPD recall antigen following sCTLA-4 inhib-
ition (Fig. 5 and Table 2), but there were no significant
changes in levels of IL-17 or IL-10 following blockade of
sCTLA-4. In contrast, sCTLA-4 blockade in resting
PBMC from SLE patients raised both cell proliferation
and IL-10 levels (Fig. 5 and Table 2), suggesting that
PBMC in lupus patients seem primed to secrete higher
levels of IL-10.
Discussion
In this study we conducted a comprehensive review of
PBMC responses to peptide autoantigens associated with
SLE, and for the first time demonstrated qualitative dif-
ferences in the responsive cytokine profile to autoanti-
genic peptides between SLE patients and healthy donors,
together with an analysis of a role for sCTLA-4. In our
study, of five autoantigenic peptides previously identified
to contain T-cell stimulatory epitopes [3, 22, 23], three
(H391-105, H471-93, and U170K131-151) were universally
immunogenic for both SLE patients and healthy volun-
teer donors, allowing us to observe that lupus patients
respond very differently to peptide autoantigens com-
pared with healthy donors. This difference also extended
to the immunoregulatory function of sCTLA-4, because
removing its regulatory function accentuated differences
between healthy and patient donor responses.
Soluble CTLA-4 is derived from an alternatively
spliced isoform of full-length CTLA-4 and is secreted by
several cell types including Treg [25], monocytes [27],
melanoma cell lines [28], and pituitary gland cells [29],
but its effects remain largely unexplored despite the clin-
ical relevance of CTLA-4 both in autoimmune disease
and cancer. High sCTLA-4 serum levels have previously
been identified in lupus patients, and low efficiency of
production was mooted to be associated with a suscepti-
bility CT60 SNP genotype of CTLA-4 [30, 31].
The question here was could lupus-associated peptide
autoantigens induce increased levels of sCTLA-4 in
either patients or healthy donors? The answer was yes,
but only in particular individuals. The question of why
some individuals have the capacity to increase sCTLA-4
in response to antigens points to a particular primed
T-cell subset with that capacity. Identifying methods
for isolating and expanding such T-cell populations
could offer a way forward for future understanding of
immune regulation in SLE.
Blockade of sCTLA-4 revealed significant response
differences between PBMC from healthy donors and
SLE patients with only IL-10 levels increasing following
PPD or peptide stimulation in the SLE patient group,
suggesting that any response enhancement by blocking
sCTLA-4 function is likely to reflect the predominant
T-cell phenotype and the associated cytokine response,
in this case IL-10. This points to a more general
sCTLA-4 effect in which it may regulate the activity of
antigen-specific effector responses but does not drive,
in the short term at least, a skewing towards a particu-
lar cytokine profile produced by those activated T cells.
In effect, sCTLA-4 most probably exerts its immunosup-
pressive effect by simply blocking B7/CD28 interactions,
thus raising the threshold before which successful T-cell
co-stimulation can occur.
Regarding the use of recombinant CTLA-4 products,
e.g. CTLA4-Ig, in SLE, a key question is whether natural
sCTLA-4 is functionally comparable. Previous studies
identified sCTLA-4 to engage with B7 molecules and to
effectively compete with CTLA4-Ig for binding [18, 32],
but there are no hard data on relative binding affinities
of sCTLA-4 with the full-length CTLA-4 receptor for
Table 2 Summary of anti-sCTLA-4 mAb blockade effect on healthy donor and SLE patient peripheral blood mononuclear cell
responses to control antigens and three stimulatory peptide autoantigens (H391-105, H471-93, and U170K131-151)
Peptide Dose Proliferation IFN-γ IL-17 IL-10
(μg/ml) Healthy SLE Healthy SLE Healthy SLE Healthy SLE
Resting† - ns ***⇩ ns ns ns ns ns ***⇧
U170K 10 *⇩ **⇩ ns ns ns *⇩ ns **⇧
20 *⇩ *⇩ ns ns ns **⇩ ns ns
H3 10 ns ns ns ns ns *⇩ ns ns
20 ns **⇧ ns ns ns ns *⇩ *⇩
H4 10 **⇩ ns ns ns *⇩ ns *⇩ ***⇧
20 ns ns ns ns ns ns ns ***⇧
PPD 5 **⇧ ns ***⇧ ns ns ns ns *⇧
αCD3 5 ns *⇩ ns **⇩ ns *⇩ ns ns
*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001
CD cluster of differentiation, H3, histone 3, H4 histone 4, IFN interferon, IL interleukin, ns not significant, PPD purified protein derivative, SLE systemic lupus
erythematosus, U170K U1 small nuclear ribonucleoprotein 70 kDa
† = resting PBMC at day 5. Arrows next to probabilty asterix represent significant increase or decrease in test sample
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B7 ligands. Our initial analysis of affinity-purified and
recombinant sCTLA-4 structure indicates that it forms
functional dimers mediated by a cysteine residue in the
C-terminal amino acid sequence unique to sCTLA-4
(manuscript in preparation). This makes it more likely
that affinity of sCTLA-4 for B7.1/B7.2 is comparable
with that of both full-length CTLA-4 receptor and recom-
binant CTLA4-Ig. It is likely, therefore, that sCTLA-4 is
functionally relevant to immune responses, but how
serum levels in patients might impact on any CTLA-4-
based therapy is unknown.
Perhaps the most surprising aspect of this study was
the identification of a clear difference in the profile of
cytokines produced in response to the peptide autoanti-
gens between healthy or lupus patient PBMC. Healthy
donors responded to the peptides by proliferating and
producing higher levels of both IFN-γ and IL-17,
whereas PBMC from lupus patients also proliferated but
secreted IL-10. This supports the notion that, in lupus,
T-cell responses are acting to support autoreactive B-cell
responses and the production of high-affinity IgG auto-
antibodies [33–36]. While IL-10 is generally considered
an anti-inflammatory cytokine, serum levels are often
raised in lupus patients where it can act as a potent
B-cell growth factor, driving autoantibody produc-
tion, class switching, and plasmablast differentiation
[33, 35, 37]. Thus, IL-10 may be important for suppress-
ing tissue damage from activated pro-inflammatory
macrophages and neutrophil responses to immune
complex deposits, but can also contribute indirectly to
the development of pathogenic immune complexes by
raising high-affinity anti-nucleic acid and nucleopro-
tein autoantibody levels, a process remote from the
inflammatory lesion [33]. It is of great interest, there-
fore, that responsive peptide autoantigen-specific T
cells are a source of this IL-10.
This study provides evidence of a role for sCTLA-4
in immune regulation, yet clearly we need to under-
stand more about the mechanistic processes which
drive its production in response to antigen. One key
issue that remains to be addressed is what is the pri-
mary stimulus of sCTLA-4 production? It is likely that
Fig. 4 Effect of anti-sCTLA-4 mAb blockade on immune responses
to H471-93 peptide isolated from PBMC of healthy donors (left panels)
or SLE patients (right panels). PBMC were incubated with H471-93 (20
μg/ml) in the presence of JMW-3B3 anti-sCTLA-4 mAb or an IgG1
isotype antibody (both 10 μg/ml) for 5 days before analysis of cellular
proliferation and levels of cell culture supernatant cytokines (IFN-γ, IL-17,
IL-10, and sCTLA-4; n= 45 per group; *p < 0.05, **p< 0.01, ***p < 0.001,
non-parametric Mann-Whitney U test; median values are shown).
CPM counts per minute, IFN interferon, IL interluekin, ns not
significant, sCTLA-4 soluble cytotoxic T lymphocyte antigen 4,
SLE systemic lupus erythematosus
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production of sCTLA-4 in response to antigen relies
both on antigen-specific T-cell responses but also the
environmental milieu. We have recently observed that
TGF-β2 is an important stimulatory factor of sCTLA-4
and it is now important to identify other stimulatory or
suppressive factors that regulate the production of
sCTLA-4.
Conclusions
SLE patients present different cytokine response patterns
to lupus-associated autoantigenic peptides compared to
healthy donors, secreting significantly higher levels of IL-
10. The natural immunosuppressant, sCTLA-4, supresses
antigen-specific cytokine responses and antibody blockade
of its activity enhances cytokine responses in healthy and
lupus patient donors, independent of which cytokine is
being secreted. Some individual responses indicated that
peptides can induce increased production of sCTLA-4 but
this effect was not significant at a population level for
lupus peptide autoantigens.
Immunostimulatory peptide autoantigens including those
investigated here may, therefore, be pivotal in driving the
disease process, raising the prospect that targeting antigen-
specific T cells to actually produce less IL-10, and allowing
the immune response to progress to full resolution, could
be a viable route to reduce immune complex-mediated
pathology in lupus.
Additional file
Additional file 1: Full analysis of individual patient and donor peptide
response datasets used to generate the summary data presented in
Fig. 3. (DOCX 495 kb)
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